# NO-dependent CaMKII activation during $\beta$ -adrenergic stimulation of cardiac muscle

### D. Gutierrez, M. Fernandez-Tenorio, J. Ogrodnik, E. Niggli

Department of Physiology, University of Bern, Bern, Switzerland

#### **Corresponding author:**

Ernst Niggli, MD
Department of Physiology
University of Bern
Bühlplatz 5
CH-3012 Bern
Switzerland

Fax: +41 31 631 4611 Tel: +41 31 631 8730 Email: niggli@pyl.unibe.ch

# **Abstract**

**Aims:** During β-adrenergic receptor (β-AR) stimulation, phosphorylation of cardiomyocyte ryanodine receptors (RyRs) by protein kinases may contribute to an increased diastolic  $Ca^{2+}$  spark frequency. Regardless of prompt activation of PKA during β-AR stimulation, this appears to rely more on activation of CaMKII, by a not yet identified signaling pathway. The goal of the present study was to identify and characterize the mechanisms which lead to CaMKII activation and elevated  $Ca^{2+}$  spark frequencies during β-AR stimulation in single cardiomyocytes in diastolic conditions.

**Methods and results:** Confocal imaging revealed that β-AR stimulation increases endogenous NO production in cardiomyocytes, resulting in NO-dependent activation of CaMKII and a subsequent increase of diastolic Ca<sup>2+</sup> spark frequency. These changes of spark frequency could be mimicked by exposure to the NO donor GSNO and were sensitive to the CaMKII inhibitors KN-93 and AIP. In-vitro, CaMKII became nitrosated and its activity remained increased independent of Ca<sup>2+</sup> in the presence of GSNO, as assessed with biochemical assays.

**Conclusions:** β-AR stimulation of cardiomyocytes may activate CaMKII by a novel direct pathway involving NO, without requiring Ca<sup>2+</sup> transients. This crosstalk between two established signaling pathways may contribute to arrhythmogenic diastolic Ca<sup>2+</sup> release and Ca<sup>2+</sup> waves during adrenergic stress, particularly in combination with cardiac diseases. In addition, NO dependent activation of CaMKII is likely to have repercussions in many cellular signaling systems and cell types.

Keywords: CaMKII; Ca sparks; Ca waves; NO-synthase

# 1. Introduction

In cardiac excitation-contraction coupling (EC-coupling) Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release (CICR) is the mechanism that amplifies the Ca<sup>2+</sup> signal initiated by entry of Ca<sup>2+</sup> via voltage-dependent Ca<sup>2+</sup> channels.<sup>1</sup> During each systole, CICR generates a robust Ca<sup>2+</sup> transient by releasing Ca<sup>2+</sup> from the sarcoplasmic reticulum (SR) via Ca<sup>2+</sup> release channels (a.k.a. ryanodine receptors or RyRs). These are macromolecular complexes located in diadic clefts, microdomains of junctional SR, in close apposition to L-type Ca<sup>2+</sup> channels.<sup>2</sup> Each group of RyRs and L-type Ca<sup>2+</sup> channels forms a unit called couplon which can create elementary Ca<sup>2+</sup> release events, Ca<sup>2+</sup> sparks.<sup>3</sup> Faithful RyR functioning is crucial in the context of cardiac muscle Ca<sup>2+</sup> release, its synchronization and strength of contraction. Disturbances of these elementary mechanisms have been observed during various cardiac pathologies.<sup>4,5</sup>

Upon β-adrenergic receptor (β-AR) stimulation during emotional stress or physical exercise, key proteins of  $Ca^{2+}$  signaling, such as the L-type  $Ca^{2+}$  channels, the RyRs and phospholamban are phosphorylated by protein kinases, <sup>6,7</sup> enhancing  $Ca^{2+}$  cycling. There is recent evidence indicating that elevated phosphorylation levels of the RyR mediated by protein kinase A (PKA) and  $Ca^{2+}$ /calmodulin-dependent protein kinase II (CaMKII) may increase their activity <sup>8-11</sup> (for reviews see <sup>7,12</sup>). During chronic β-AR stimulation, this could constitute a  $Ca^{2+}$  leak and deplete the SR of  $Ca^{2+}$ , which would reduce the amplitude of  $Ca^{2+}$  transients, eventually contributing to weak heartbeats. <sup>13</sup> Experimentally, it has proven difficult to clearly assign a role for the different kinases in modulating RyR behavior. The generation of various transgenic mouse lines, specifically targeting phosphorylation by PKA and CaMKII, has not clarified the situation and provided apparently contradictory results and interpretations. However, analysis of  $Ca^{2+}$  spark frequencies in transgenic mice expressing constitutively phosphorylated RyRs

(S2808D, S2814D) suggested that PKA and CaMKII-dependent phosporylation may increase resting Ca<sup>2+</sup> spark frequencies.<sup>5,9</sup>

Here we examined Ca<sup>2+</sup> sparks as signals closely reflecting RyR open probability in their native environment. While there is controversial literature on the relative importance of PKA and/or CaMKII-dependent RyR phosphorylation, <sup>8,14</sup> only few studies specifically investigated changes of Ca<sup>2+</sup> spark frequencies resulting from β-AR stimulation during diastole or in resting cardiomyocytes. <sup>5,9,15,16</sup> Based on these findings, it has been suggested that PKA-dependent phosphorylation of RyRs may not be significantly involved in the observed increase of the resting Ca<sup>2+</sup> spark frequency. It has been reported that this entirely hinged on the SERCA stimulation resulting from phosphorylation of phospholamban<sup>17</sup> or occurred via a pathway that could involve CaMKII. <sup>14,16,18-20</sup> Since the CaMKII-dependent increase of spontaneous spark frequencies was observed in resting cardiomyocytes without detectable Ca<sup>2+</sup> signals, which are typically required for significant Ca<sup>2+</sup>-dependent activation of CaMKII, <sup>21,22</sup> it remained unresolved by which pathway(s) CaMKII would become activated under these conditions.

The current study represents an effort to reveal the mechanism involved in the activation of CaMKII in resting cardiomyocytes during β-AR stimulation, and to identify an alternative pathway that could underlie the observed increase in Ca<sup>2+</sup> spark frequency. In the literature, several possible mechanisms have been mentioned. The "exchange protein activated by cAMP" (Epac) may participate in the modulation of RyR open probability, either directly or via CaMKII. Another alternative is activation of CaMKII by reactive oxygen species (ROS), which is known to occur independently of detectable Ca<sup>2+</sup> signals. Therefore, we carried out experiments investigating Ca<sup>2+</sup> sparks and CaMKII activity to characterize the putative involvement of these and other cellular signaling pathways.

Together our findings reveal that upon  $\beta$ -AR stimulation CaMKII becomes activated in a manner that does not require Ca<sup>2+</sup> transients, initiated by formation of endogenous nitric oxide (NO). This represents an unexpected and newly discovered mode of CaMKII activation occurring in parallel to PKA. Preliminary findings have previously been presented in abstract form.<sup>24</sup>

# 2. Methods

For additional information on methods, see Supplementary information online.

#### 2.1 Isolation of Guinea-pig ventricular myocytes

For all electrophysiological and confocal Ca<sup>2+</sup> and NO imaging experiments, we used freshly isolated Guinea-pig ventricular cardiomyocytes<sup>16</sup> following the animal handling procedures conforming with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (1996) and with the permission of the State Veterinary Administration and according to Swiss Federal Animal protection law (permit BE97/09). Animals were euthanized by stunning and cervical dislocation, followed by rapid removal and enzymatic dissociation of the cardiac tissue.

#### 2.2 Experimental solutions

All drugs, inhibitors and donors used during our experiments were freshly prepared daily from aliquots. Extracellular and intracellular (patch pipette) solutions were used from a ready made stock.<sup>16</sup>

## 2.3 Electrophysiological recordings

I<sub>Ca</sub> recordings were carried out in the whole-cell configuration of the patch clamp technique, resting membrane potential was set at -80mV during Ca<sup>2+</sup> imaging.<sup>16</sup>

## 2.4 SR Ca<sup>2+</sup> content preconditioning

To ensure a constant SR Ca<sup>2+</sup> content, we performed a SR Ca<sup>2+</sup> loading protocol with a train of 20 membrane depolarizations from -80 to 0 mV (see *Figure 1A*).

Pharmacological interventions were applied, as indicated. Changes in SR Ca<sup>2+</sup> content were compared to control conditions without the drug, after an identical loading protocol. In all cases content was estimated by recording a Ca<sup>2+</sup> transient triggered with caffeine.

## 2.5 Confocal Ca<sup>2+</sup> and NO imaging

The Ca<sup>2+</sup> spark frequency and SR Ca<sup>2+</sup> content are shown after normalization and expressed as mean values ±S.E.M. For these recordings we used fluo-3 as Ca<sup>2+</sup> indicator. NO measurements were carried out using DAF-2DA. Confocal imaging was performed with either a FluoView-1000 (Olympus) or a MRC-1000 confocal laser-scanning microscope (Bio-Rad). Indicators were excited at 488 nm with a solid-state laser (Sapphire 488-10) and fluorescence was detected > 515 nm.

#### 2.6 In-vitro CaMKII<sub>δ</sub> activity and nitrosation assays

Ca<sup>2+</sup>-independent, H<sub>2</sub>O<sub>2</sub> and NO-dependent CaMKII activities were assessed by using an ELISA kit. Values are shown normalized to the maximal CaMKII activation levels reached in low Ca<sup>2+</sup> (<10 nM Ca<sup>2+</sup>; CaM/EGTA). Nitrosation of CaMKII was quantified using an antibody specifically detecting S-nitrosated cysteines.

#### 2.7 Statistics

Paired or unpaired Students t-tests were applied as appropriate to determine significance. In figures p values of < 0.05 or < 0.01 are indicated by \* or \*\*, respectively. N refers to number of animals, n to number of cells.

# 3. Results

# 3.1 $\text{Ca}^{2+}$ spark frequency during $\beta$ -AR stimulation is modulated by CaMKII but not PKA

We investigated cAMP-dependent pathways (e.g. PKA, Epac) to determine the involvement of PKA and/or CaMKII in the modulation of resting Ca<sup>2+</sup> spark frequencies. Constant SR loading was achieved with Ca<sup>2+</sup> preloading involving a train of L-type Ca<sup>2+</sup> currents. SR Ca<sup>2+</sup> content was estimated with caffeine before and after the experiment in each cardiomyocyte (see Figure 1A and 16). As shown in Figure 1B and 1C, superfusion of resting cells with 1 µM isoproterenol (Iso) increased the frequency of Ca<sup>2+</sup> sparks around 4-fold within 3 min, without significantly altering the [Ca<sup>2+</sup>]<sub>SB</sub> in this time window (see Figure 1E and 16). Next, cAMP was raised independently of the β-AR receptors by direct activation of adenylate cyclase with forskolin. 11 Surprisingly, and unlike Iso, 1 µM forskolin did not change the Ca2+ spark frequency significantly, even though the SR content increased to 125 %, presumably resulting from SERCA stimulation without activation of sparks in parallel. Importantly, both drugs resulted in almost identical amplification of the L-type Ca2+ current (ICa), confirming that forskolin activated PKA to an extent corresponding to Iso application (Figure 1D). Inclusion of the specific PKA inhibitory peptide PKI in the patch solution did not prevent the increase in the Ca<sup>2+</sup> spark frequency, but resulted in a drop of SR Ca<sup>2+</sup> content, presumably resulting from the suppression of SERCA stimulation during Iso.

These results indicate that acute  $\beta$ -AR stimulation increases  $Ca^{2+}$  spark frequency, independently of cAMP and therefore makes an involvement of PKA and Epac very unlikely. Hence, we did not follow up on either of these pathways. A potential alternative pathway could be CaMKII, despite the fact that in quiescent cells, there were no  $Ca^{2+}$  signals that could activate this kinase. To confirm involvement of CaMKII, as also

suggested by our previous study,<sup>16</sup> we carried out experiments in the presence of either KN-93 or KN-92 or included 10 µM of the specific CaMKII inhibitor autocamtide-2-related inhibitory peptide (AIP) in the patch solution. KN-93 and AIP prevented the increase in Ca<sup>2+</sup> spark frequency in Iso without changing the SR Ca<sup>2+</sup> content (*Figure 2A-C*). KN-92, the inactive negative control for KN-93, did not suppress the increase in spark frequency, as expected. Thus, under these experimental conditions, we can use the Ca<sup>2+</sup> spark frequency as biological indicator for CaMKII activity.

## 3.2 ROS scavengers fail to prevent the increase in Ca2+ spark frequency

We then examined whether  $Ca^{2+}$ -independent CaMKII activation by  $ROS^{23}$  could underlie the higher spark frequency. For this we used Mn-TBAP, a superoxide dismutase (SOD) mimetic, which has previously been shown in our experiments to reliably suppress  $Ca^{2+}$  sparks initiated by oxidative stress.<sup>25</sup> Interestingly, 100  $\mu$ M Mn-TBAP failed to prevent the increase in  $Ca^{2+}$  spark frequency and did not significantly alter SR  $Ca^{2+}$  load (*Figure 2D-F*), indicating that CaMKII activation by  $\beta$ -AR stimulation is not ROS-dependent.

## 3.3 NO modulates Ca<sup>2+</sup> spark frequency upon β-AR stimulation

It has been suggested that after  $\beta$ -AR stimulation the increase in SR Ca<sup>2+</sup> leak, determined with a dedicated leak protocol, is dependent on NO production and independent of PKA, because NO-synthase (NOS) inhibition prevented the leak observed in the presence of Iso.<sup>11,26</sup> To examine whether a similar mechanism could be involved in the higher frequency of Ca<sup>2+</sup> spark observed here, we inhibited the synthesis

of NO while stimulating the cardiomyocytes with Iso, analogous to experiments described in *Figure 1*. Pretreatment with 500  $\mu$ M of the NOS inhibitor L-NAME prevented a significant increase in Ca<sup>2+</sup> spark frequency (F*igure 3A*), indicating that upon  $\beta$ -AR stimulation, the spark frequency is modulated by endogenous NO produced by NOS of the cardiomyocyte.

To confirm NO involvement, cells were loaded with diaminofluorescein (DAF-2) by exposure to the ester (DAF-2DA; 0.1 µM). After application of Iso, we recorded a substantial increase in DAF-2 fluorescence (19% ± 5%; Figure 3C and E). In some cells the NO donor S-Nitroso-L-glutathione (GSNO; 500 µM) was added at the end of the protocol, to confirm that DAF-2 resolves NO signals (Figure 3D). Please note that these recordings were corrected for dye bleaching and should not be taken quantitatively for NO concentrations. Because DAF-2 has been reported to detect other types of reactive species<sup>27</sup>, we repeated the same experiment in 500 µM L-NAME to suppress NO formation. This prevented the increase in DAF-2 fluorescence (Figure 3E and 3F, orange symbols and columns), confirming that the signal reflects NO production. Cellular ROS production induced by GSNO was excluded with the ROS sensitive fluorescent indicator CM-H<sub>2</sub>DCF (see supplementary *Figure S1*). Together these findings firmly establish a link between Iso-induced production of intracellular NO by the cardiomyocytes and the observed increase of Ca<sup>2+</sup> spark frequencies mediated by CaMKII. This interpretation is in line with the inability of Mn-TBAP to prevent the increase in Ca<sup>2+</sup> spark frequency (Figure 2D and 2E) and is consistent with the observation that Mn-TBAP does not significantly scavenge NO.<sup>28</sup>

3.4 The NO donor GSNO reproduces the increase in  $Ca^{2+}$  spark frequency induced by  $\beta$ -adrenergic stimulation

NO can affect the function of proteins, including the RyRs, via several known pathways. 29-31 This can occur directly as post-translational protein modifications, such as S-nitrosation (also referred to as S-nitrosylation or transnitrosylation). 12,32 Alternatively, NO can lead to the formation of cGMP and activation of protein kinase G (PKG), which has been shown to phosphorylate RyRs, but so far only in-vitro. 33 The findings in Figure 3 indicate that after Iso application, NO mediates the increase in Ca<sup>2+</sup> spark frequency. To support this interpretation, we used a NO donor instead of Iso. 150 µM GSNO resulted in a 3.22 (± 0.31)-fold increase in Ca2+ spark frequency, thereby quantitatively mimicking the changes observed in Iso (Figure 4A and 4B). Note that in these experiments SR Ca2+ content did not maintain the control level, presumably because GSNO increased the Ca<sup>2+</sup> spark frequency without concomitant SERCA stimulation (Figure 4C). To distinguish between a direct S-nitrosation of the RyRs and an indirect modification via CaMKII (suggested by the findings above), we tested whether AIP could prevent the GSNO-dependent occurrence of sparks, similar to what was observed in Iso. In the presence of AIP, GSNO did not significantly elevate spark frequency (Figure 4B). These findings confirm that the higher spark frequency in GSNO resulted largely from activation of CaMKII and not from a direct S-nitrosation of the RyRs or activation of PKG. In summary, these data indicate that NO can activate CaMKII, in the absence of Ca<sup>2+</sup> signals.

#### 3.5 Quantification of NO-dependent CaMKII activation in-vitro

To confirm that NO could activate CaMKII in the absence of elevated  $Ca^{2+}$ , we used an *in-vitro* assay.<sup>34</sup> CaMKII activity was detected with an ELISA test and normalized to that observed in low  $Ca^{2+}$  (< 10 nM;  $Ca^{2+}$ , CaM and EGTA, *Figure 4D*). As already established,<sup>23</sup> addition of  $H_2O_2$  activated CaMKII in low  $Ca^{2+}$ . The activity observed in 1

 $\mu$ M H<sub>2</sub>O<sub>2</sub> was 2.65 (± 0.47)-fold higher than in control. The NO donor GSNO resulted in comparable CaMKII stimulation of 2.31 (± 0.39)-fold. CaMKII activity under these oxidative and nitrosative conditions represented ~16% of the maximal Ca<sup>2+</sup>/CaM dependent activity (250 μM Ca<sup>2</sup> and 120 nM calmodulin). This confirms a direct activation of CaMKII by NO, as suggested by our findings in cardiomyocytes. Each CaMKII monomer is predicted by GPS-SNO software<sup>35</sup> to have 3 potential sites for S-nitrosation (*Figure 4E* upper panel). We used an antibody specifically recognizing S-nitrosated cysteines to quantify CaMKII nitrosation after pre-incubation of CaMKII $_{\delta}$  with GSNO (*Figure 4E* lower panel). Indeed, a 32.1% ± 13% increase of CaMKII nitrosation was observed with this assay.

## 3.6 GSNO leads to arrhythmogenic Ca<sup>2+</sup> signals In beating cardiomyocytes

At the cellular level, spontaneous  $Ca^{2+}$  waves (SCWS) are considered to be indicators for arrhythmogenic conditions. Since the elevated  $Ca^{2+}$  spark frequencies shown above could result in SCWS, we tested the arrhythmogenic potential of the NO donor in field stimulated cardiomyocytes (*Figure 5*). In these experiments, NO presumably modifed several relevant  $Ca^{2+}$  signaling proteins and membrane channels. However, the recordings revealed an increase in the diastolic  $Ca^{2+}$  spark frequency, similar to what was observed in resting cells. Furthermore, after a train of 10 depolarizations, 13.3% of the control myocytes exhibited SCWS, while in the presence of GSNO 77.8% showed waves. This elevated wave frequency was accompanied by a reduced SR content (to 77%  $\pm$  6.5% of control), confirming that the waves were resulting from altered function of the RvRs and not from SR  $Ca^{2+}$  overload.

Taken together, our results provide compelling evidence that the observed increase in Ca<sup>2+</sup> spark frequency upon β-AR stimulation results from an activation of CaMKII, which

is mediated by NO but is not dependent on Ca<sup>2+</sup> transients (see *Figure* 6 for a diagram of this pathway). This represents a new mechanism for CaMKII activation that may have far reaching implications.

## 4. Discussion

RyRs have attracted considerable research interest, due to discoveries such as RyR mutations causing life threatening arrhythmias.<sup>36</sup> alterations of their behavior during several diseases, which are often caused by posttranslational modifications, most notable phosphorylation and oxidation/nitrosation (for review see<sup>12</sup>). The participation of the RyRs in diseases such as catecholaminergic polymorphic ventricular tachycardias (CPVTs) and heart failure suggests that they may be potential drug targets.<sup>37,38</sup>

#### 4.1 Modulation of RyR function

Changes of RyR function are expected to have a significant impact on cardiac Ca<sup>2+</sup> signaling. Several laboratories have examined functional consequences of RyR phosphorylation on various levels of complexity, from single channels to isolated cells, partly using transgenic animal and disease models.<sup>7,39,40</sup> These studies have resulted in a considerable controversy and confusion regarding the functional role of the involved protein kinases PKA and CaMKII.<sup>14,41</sup> The reasons for this are not clear, but may arise from different disease models, protocols and experimental designs. As suggested by the present study, they may partly arise from unexpected cross-talks between complex cellular signaling pathways.

#### 4.2 Modes of CaMKII activation

When examining the importance of protein kinases for changes of diastolic Ca<sup>2+</sup> spark frequencies after β-AR stimulation, we made a surprising observation. Even though there were no visible Ca<sup>2+</sup> signals in resting cells that could lead to significant CaMKII activation, the increase in Ca2+ spark frequencies could be prevented by pharmacologically blocking CaMKII (but not PKA). This immediately raised the question how under these circumstances CaMKII could become activated? In the literature, several possibilities have been reported, including a pathway involving "exchange factor directly activated by cAMP" (Epac), 15,42 or requiring oxidative modification of the CaMKII.<sup>23</sup> The observation that the application of forskolin did not elevate the propensity of diastolic Ca<sup>2+</sup> sparks, unlike β-AR stimulation, is in line with our conclusion, based on the experiments with protein kinase inhibitors for CaMKII and PKA, that any PKA involvement is highly unlikely. Furthermore, the negative result with forskolin regarding spark frequencies makes activation of CaMKII via the Epac pathway improbable and is consistent with the finding that forskolin does not increase SR Ca2+ leak. 11 Therefore, we carried out experiments to test for the second possibility of Ca<sup>2+</sup> spark activation. oxidative stress. Of note, redox modifications of the RyRs are well known to increase their openings<sup>43,44</sup> although direct RvR oxidation would not be sensitive to the CaMKII inhibitor AIP, as observed in this study. Thus, we were left with the alternative that an oxidative modification of CaMKII could be responsible for its activation. However, we were unable to prevent the Ca<sup>2+</sup> sparks with Mn-TBAP, a SOD mimetic which we found to reliably suppress ROS induced sparks in a model of oxidative stress.<sup>25</sup> This finding suggests that ROS generation after β-AR stimulation is not involved in CaMKII activation and is consistent with a recent report showing that ROS production does not increase during β-AR stimulation of resting cells. 45

## 4.3 NO activates CaMKII in cardiomyocytes

An interesting observation has been reported in a study examining SR Ca<sup>2+</sup> leaks in cardiomyocytes during β-AR stimulation using a dedicated leak protocol. 11 In this study, the SR Ca<sup>2+</sup> leak has been quantified from the drop of the cytosolic Ca<sup>2+</sup> concentration after blocking the RyRs with tetracaine. These authors showed that the function of CaMKII, but also NO synthases, were important determinants for the SR Ca<sup>2+</sup> leak.<sup>26</sup> Surprisingly, our experiments along these lines revealed that inhibition of NOS also prevented the increase in spark frequency, suggesting an involvement of NO signaling. To confirm a key role of NO we used a multi-pronged approach. We were able to detect endogenous NO production by the cardiomyocytes upon Iso application, while the NO donor GSNO mimicked the effects of Iso on the spark frequency. In contrast, the GSNO effect was almost completely inhibited by the specific CaMKII inhibitor AIP, suggesting that direct RyR nitrosation was not involved. Rather this appeared to be mainly mediated by CaMKII. Could it be that NO maintains CaMKII active at resting Ca<sup>2+</sup> concentrations, similar to what has been reported for ROS?<sup>23</sup> For this to occur, an initial Ca<sup>2+</sup>-dependent activation of CaMKII is required, which could be mediated by invisible Ca2+ signals, such as the Ca<sup>2+</sup> guarks suggested to underlie a fraction of the SR Ca<sup>2+</sup> leak. 46,47 To address the intriguing question of NO-dependent CaMKII activation directly, we applied a biochemical in-vitro assay of CaMKII activity. The results obtained confirmed that NO can maintain CaMKII active to an extent similar to H<sub>2</sub>O<sub>2</sub>, without requiring elevated Ca<sup>2+</sup> concentrations. Since this occurred in-vitro and was initiated by significant S-nitrosation of the CaMKII protein, it seems very likely that NO can directly activate CaMKII. Interestingly, a strikingly different regulation by NO and ROS has been reported for the CaMKII<sub>d</sub> isoform of this kinase in pituitary tumor GH3 cells. This isoform was inhibited after nitrosation, but became activated in reducing conditions.<sup>48</sup>

#### 4.4 Relevance of NO-dependent CaMKII activation

Taken together, these findings provide compelling evidence for a stimulation of endogenous NO generation by cardiomyocytes upon  $\beta$ -AR stimulation. In the beating heart, this presumably additive mechanism may be even more pronounced, since further CaMKII activation will occur by enhanced Ca<sup>2+</sup> transients. Several studies have previously reported positive or negative inotropic effects of NO, which may be partly related to modifications of CaMKII and RyR function, involved NOS isoforms, or crosstalk between activated pathways. <sup>49,50</sup> Related to this, it has been suggested that NO may have a biphasic effect on RyR open probability, depending on the extent of preexisting  $\beta$ -AR stimulation. <sup>51</sup> Although the precise mechanism of this phenomenon remains unresolved, it may involve CaMKII and could be related to changes of the nitroso/redox balance, as several posttranslational modifications will modulate RyR function in an exceedingly complex fashion. <sup>52</sup>

The pathway characterized here represents a newly discovered mechanism for CaMKII activation. This results in a surge of diastolic  $Ca^{2+}$  sparks and increased wave propensity. Since  $Ca^{2+}$  sparks are signals faithfully reporting the function of the RyRs, this likely occurs via CaMKII-dependent modulation of the RyRs. In addition, the direct activation of CaMKII by NO observed here and the pathways participating downstream of CaMKII are expected to have additional repercussions for cardiomyocyte  $Ca^{2+}$  signaling. For example, NO mediated CaMKII activation contributes to the modulation of  $Ca^{2+}$  cycling upon  $\beta$ -AR stimulation, such as during physical exercise or emotional stress. During sustained  $\beta$ -AR stimulation, such as during heart failure, this could lead to SR  $Ca^{2+}$  depletion, weaker heart beat and arrhythmias. The additional CaMKII activation prompted by NO may be particularly detrimental if it occurs in conditions with already hypersensitive RyRs, for example in the presence of CPVT mutations or oxidative RyR modifications.

Finally, the identification of this pathway adds to the experimental complexity of studies with cardiac muscle because it represents a possibility for crosstalk between PKA and CaMKII activation, downstream of  $\beta$ -AR stimulation. The existence of such a cross-talk may explain some of the controversial experimental results and interpretations regarding the regulation of the RyRs by PKA or CaMKII respectively.

### **Funding**

This work is supported by grants from the Swiss National Science Foundation (31-132689 and 31-109693 to E.N.) and by an Instrumentation Grant of the Medical Faculty, University of Bern.

### **Acknowledgements**

We would like to thank Dr. N. Ullrich and I. Marcu for experimental support, as well as D. Lüthi and M. Känzig for technical assistance.

## **Conflicts of interest**

None.

# **Figure Legends**

Figure 1 The increase of Ca<sup>2+</sup> spark frequency by Iso is mediated by β-adrenergic receptors but not by cAMP. (A) The experimental protocol used trains of depolarizations to load the SR with Ca2+ and caffeine to estimate SR Ca2+ content (for details see Supplementary online information). (B) Confocal line-scan images showing Ca<sup>2+</sup> sparks in control solution (Ctrl) and after ~3 min of 1 µM Iso or 1 µM forskolin. (C), Normalized Ca<sup>2+</sup> spark frequency in Ctrl, after ~3 min of Iso (n=8, N=8) or forskolin (n=6, N=2) and after Iso in the presence of the PKA inhibitor PKI (n=7, N=3), respectively. In control, Ca<sup>2+</sup> sparks are relatively indistinct and sparse in resting guinea pig cardiomyocytes<sup>16</sup> (around 1 s<sup>-1</sup> 100 µm<sup>-1</sup>). While Iso led to a ~4 fold increase in Ca<sup>2+</sup> spark frequency, this was not observed with forskolin and was not prevented by the PKA inhibitor PKI. (D) Ca<sup>2+</sup> current in Ctrl and after ~3 min Iso or forskolin. For this experiment the cells were held at -40 mV to inactivate Na<sup>+</sup> currents. Normalized Ca<sup>2+</sup> current in Iso (n=5, N=4) or forskolin (n=6, N=5). Current stimulation by forskolin was similar to that by Iso, documenting comparable PKA activation. (E) Typical SR Ca<sup>2+</sup> content assessment by 10 mM caffeine. In forskolin, SR content is increased to 125% ± 8.8% (n=15, N=5) because of SERCA stimulation without activation of sparks. In contrast, in PKI the SR Ca2+ content decreased, partly because PKA inhibition prevents SERCA stimulation.

**Figure 2** CaMKII is involved in spark frequency modulation, but not via ROS-dependent CaMKII activation. (*A*) Line-scan images in Ctrl and after 1 μM Iso, both in the presence of 10 μM of AIP in the patch pipette. (*B*) Ca<sup>2+</sup> spark frequency in Ctrl and in Iso, in the absence (n=8, N=8) or presence of the CaMKII inhibitors AIP (n=9, N=5), KN-93 (n=5, N=2) and its inactive analogue KN-92 (n=5, N=3). (*C*) Unchanged SR Ca<sup>2+</sup> content in the presence of AIP, KN-93 and KN-92. (*D*) Line-scan images recorded after 1 hour pre-

incubation with 100 μM ROS scavenger Mn-TBAP in Ctrl and after ~3 min of 1 μM Iso. (*E*) Ca<sup>2+</sup> spark frequency during Iso without (n=8, N=8) and with Mn-TBAP (n=5, N=5). (*F*) Unchanged SR Ca<sup>2+</sup> content in the presence of the ROS scavenger Mn-TBAP. **Figure 3** The increase of Ca<sup>2+</sup> spark frequency is dependent on NO. (*A*) Comparison of the Ca<sup>2+</sup> spark frequency stimulation by 1 μM Iso without (n=8, N=8) and with (n=7, N=5) 1 hour pre-incubation with 500 μM L-NAME. (*B*) SR Ca<sup>2+</sup> content remained unchanged in the presence of L-NAME. (*C*) Representative signal of DAF-2 fluorescence before (Ctrl) and after ~3 min of 1 μM Iso. (*D*) Representative time-course of NO production upon 1 μM Iso application. At the end, GSNO is applied as a positive control for NO detection. (*E*) Averaged time-course of DAF-2 fluorescence in Ctrl and during Iso recorded in the absence (red trace n=7, N=6) and presence of L-NAME (orange trace, n=6, N=4). (*F*) Normalized NO-induced DAF-2 fluorescence upon Iso (red bar) and after pre-incubation in 500 μM L-NAME (orange bar). L-NAME prevented the NO signal observed in control, confirming that the DAF-2 fluorescence resulted from NO production.

**Figure 4.** The NO donor GSNO increases  $Ca^{2+}$  spark frequency upon CaMKII activation via nitrosation. (*A*) Line-scan images of  $Ca^{2+}$  spark recordings in Ctrl (top), during 150 μM GSNO alone (middle) and GSNO in the presence of 10 μM AIP in the patch pipette (bottom). (*B*) Normalized spark frequencies after ~3 min of 1 μM Iso (blue bar n=6, N=6) and GSNO alone (red bar n=14 N=11) and with 10 μM AIP (white bar n=9 N=4). Inhibiting CaMKII with AIP prevented the higher frequency induced by GSNO. (*C*) After GSNO, the SR  $Ca^{2+}$  content was not maintained (83% ±6% of control) due to a higher spark frequency without SERCA stimulation in parallel. (*D*) Quantitative in-vitro CaMKII activation in response to 1 μM  $H_2O_2$  (blue bar) or 500 μM GSNO (red bar) in comparison to control (white bar). CaMKII activities were normalized to full  $Ca^{2+}/CaM$ -dependent and

control activities (N=5). (*E*) Detection of nitrosated CaMKII *in-vitro* by anti-Cys-SNO specific antibody reveals increased nitrosation in GSNO.

**Figure 5.** In beating cardiomyocytes, the NO donor GSNO increased diastolic Ca<sup>2+</sup> spark frequency and induced arrhythmogenic diastolic Ca<sup>2+</sup> waves. (*A*) Protocol used to record Ca<sup>2+</sup> transients and Ca<sup>2+</sup> waves from myocytes during and immediately after stimulation, with or without the presence of GSNO. (*B*) GSNO resulted in more diastolic Ca<sup>2+</sup> sparks,(*C*) in a higher propensity for spontaneous Ca<sup>2+</sup> waves (SCWS) and (*D*) in reduced SR Ca<sup>2+</sup> content. (*E*) Statistical analysis of SCWS (n=9, N=5) and SR content (n=9, N=5).

**Figure 6.** Diagram of the involved pathways during β-AR stimulation of resting cardiomyocytes. Our results show that during β-AR stimulation by Iso, endogenous production of NO derived from NOS activates CaMKII and subsequently modulates the RvRs open probability, as reflected by the higher  $Ca^{2+}$  spark frequency.

#### **REFERENCES:**

- 1. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. *Am J Physiol Cell Physiol* 1983;**245**:C1–C14.
- 2. Bers D. Excitation-contraction coupling and cardiac contractile force. 2nd ed., Kluwer Academic Publications;2001.

- 3. Cheng H, Lederer W, Cannell M. Calcium sparks: elementary events underlying excitation-contraction coupling in heart muscle. *Science* 1993;**262**:740-744.
- 4. Gomez AM, Valdivia HH, Cheng H, Lederer MR, Santana LF, Cannell MB, McCune SA, Altschuld RA, Lederer WJ. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. *Science* 1997;**276**:800–806.
- 5. Shan J, Betzenhauser MJ, Kushnir A, Reiken S, Meli AC, Wronska A, Dura M, Chen BX, Marks AR. Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. *J Clin Invest* 2010;**120**:4375–4387.
- 6. Grimm M, Brown JH. β-Adrenergic receptor signaling in the heart: role of CaMKII. *J Mol Cell Cardiol* 2010;**48**:322–330.
- 7. Wehrens XHT, Lehnart SE, Marks AR. Intracellular calcium release and cardiac disease. *Annu Rev Physiol* 2005;**67**:69–98.
- 8. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. *Cell* 2000;**101**:365–376.
- 9. van Oort RJ, McCauley MD, Dixit SS, Pereira L, Yang Y, Respress JL, Wang Q, De Almeida AC, Skapura DG, Anderson ME, Bers DM, Wehrens XHT. Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. *Circulation* 2010;**122**:2669–2679.
- 10. Li N, Wang T, Wang W, Cutler MJ, Wang Q, Voigt N, Rosenbaum DS, Dobrev D, Wehrens XHT. Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice. *Circ Res* 2012;**110**:465–470.

- 11. Curran J, Hinton MJ, Ríos E, Bers DM, Shannon TR. Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. *Circ Res* 2007;**100**:391–398.
- 12. Niggli E, Ullrich ND, Gutierrez D, Kyrychenko S, Poláková E, Shirokova N. Posttranslational modifications of cardiac ryanodine receptors: Ca<sup>2+</sup> signaling and EC-coupling. *BBA-Mol Cell Res* 2012;**1833**;866-875.
- 13. Kushnir A, Shan J, Betzenhauser MJ, Reiken S, Marks AR. Role of CaMKII phosphorylation of the cardiac ryanodine receptor in the force frequency relationship and heart failure. *Proc Natl Acad Sci USA* 2010;**107**:10274–10279.
- 14. Bers DM. Ryanodine receptor S2808 phosphorylation in heart failure: smoking gun or red herring. *Circ Res* 2012;**110**:796–799.
- 15. Pereira L, Metrich M, Fernandez-Velasco M, Lucas A, Leroy J, Perrier R, Morel E, Fischmeister R, Richard S, Benitah JP, Lezoualc'h F, Gomez AM. The cAMP binding protein Epac modulates Ca<sup>2+</sup> sparks by a Ca<sup>2+</sup>/calmodulin kinase signalling pathway in rat cardiac myocytes. *J Physiol* 2007;**583**:685–694.
- 16. Ogrodnik J, Niggli E. Increased Ca<sup>2+</sup> leak and spatiotemporal coherence of Ca<sup>2+</sup> release in cardiomyocytes during β-adrenergic stimulation. *J Physiol* 2010;**588**:225–242.
- 17. Li L, Satoh H, Ginsburg KS, Bers DM. The effect of Ca<sup>2+</sup>–calmodulin dependent protein kinase II on cardiac excitation–contraction coupling in ferret ventricular myocytes. *J Physiol* 1997;501:17–31.
- 18. Ruiz-Hurtado G, Domínguez-Rodríguez A, Pereira L, Fernández-Velasco M, Cassan C, Lezoualc'h F, Benitah J-P, Gómez AM. Sustained Epac activation induces calmodulin dependent positive inotropic effect in adult cardiomyocytes. *J Mol Cell Cardiol* 2012;**53**:617–625.

- 19. Maier LS, Bers DM. Role of Ca<sup>2+</sup>/calmodulin-dependent protein kinase (CaMK) in excitation—contraction coupling in the heart. *Cardiovasc Res* 2007;**73**:631–640.
- 20. Currie S, Loughrey CM, Craig MA, Smith GL. Calcium/calmodulin-dependent protein kinase II-delta associates with the ryanodine receptor complex and regulates channel function in rabbit heart. *Biochem J* 2004;**377**:357–366.
- 21. Erickson JR, Patel R, Ferguson A, Bossuyt J, Bers DM. Fluorescence resonance energy transfer-based sensor camui provides new insight into mechanisms of calcium/calmodulin-dependent protein kinase II activation in intact cardiomyocytes. *Circ Res* 2011;**109**:729–738.
- 22. De Koninck P, Schulman H. Sensitivity of CaM kinase II to the frequency of Ca<sup>2+</sup> oscillations. *Science* 1998;**279**:227–230.
- 23. Erickson JR, Joiner M-LA, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O'Donnell SE, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham A-JL, Weiss RM, Spitz DR, Shea MA, Colbran RJ, Mohler PJ, Anderson ME. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. *Cell* 2008;**133**:462–474.
- 24. Gutierrez D, Ogrodnik J, Niggli E. Activation of Ca<sup>2+</sup> sparks during β-adrenergic stimulation in resting cardiomyocytes may involve CaMKII and NO, but not ROS. *Biophys J* 2012;**102**:98a.
- 25. Shkryl VM, Martins AS, Ullrich ND, Nowycky MC, Niggli E, Shirokova N. Reciprocal amplification of ROS and Ca<sup>2+</sup> signals in stressed mdx dystrophic skeletal muscle fibers. *Pflugers Arch* 2009;**458**:915–928.
- 26. Curran J, Ahmed U, Bers DM, Ziolo M, Shannon TR. Isoproterenol-enhanced diastolic sarcoplasmic reticulum Ca leak in ventricular myocytes requires activation of nitric oxide synthase. *Biophys J* 2009;**96**:120.

- 27. Planchet E. Nitric oxide (NO) detection by DAF fluorescence and chemiluminescence: a comparison using abiotic and biotic NO sources. *J Exp Bot* 2006;**57**:3043–3055.
- 28. Szabó C, Day BJ, Salzman AL. Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger. *FEBS Lett* 1996;**381**:82–86.
- 29. Lim G, Venetucci L, Eisner DA, Casadei B. Does nitric oxide modulate cardiac ryanodine receptor function? Implications for excitation-contraction coupling. *Cardiovasc Res* 2007;**77**:256–264.
- 30. Lima B, Forrester MT, Hess DT, Stamler JS. S-nitrosylation in cardiovascular signaling. *Circ Res* 2010;**106**:633–646.
- 31. Gonzalez DR, Treuer A, Sun Q-A, Stamler JS, Hare JM. S-nitrosylation of cardiac ion channels. *J Cardiovasc Pharm* 2009;**54**:188-195.
- 32. Donoso P. Modulation of cardiac ryanodine receptor activity by ROS and RNS. *Front Biosci* 2011;**16**:553–567.
- 33. Takasago T, Imagawa T, Furukawa K-I, Ogurusu T, Shigekawa M. Regulation of the cardiac ryanodine receptor by protein kinase-dependent phosphorylation. *J Biochem* 1991;**109**:163–170.
- 34. Bodhinathan K, Kumar A, Foster TC. Intracellular redox state alters NMDA receptor response during aging through Ca<sup>2+</sup>/calmodulin-dependent protein kinase II. *J Neurosci* 2010;**30**:1914–1924.
- 35. Xue Y, Liu Z, Gao X, Jin C, Wen L, Yao X, Ren J. GPS-SNO: computational prediction of protein S-nitrosylation sites with a modified GPS algorithm. *PLoS ONE* 2010;**5**:e11290.

- 36. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, Donarum EA, Marino M, Tiso N, Viitasalo M. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. *Circulation* 2001;**103**:485–490.
- 37. Lehnart SE, Terrenoire C, Reiken S, Wehrens XHT, Song LS, Tillman EJ, Mancarella S, Coromilas J, Lederer W, Kass RS. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. *Proc Natl Acad Sci USA* 2006;**103**:7906–7910.
- 38. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AAM, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. *Nat Med* 2009;**15**:380–383.
- 39. Bers DM. Calcium cycling and signaling in cardiac myocytes. *Annu Rev Physiol* 2008;**70**:23–49.
- 40. Swaminathan PD, Purohit A, Hund TJ, Anderson ME. Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. *Circ Res* 2012;**110**:1661–1677.
- 41. Valdivia HH. Ryanodine receptor phosphorylation and heart failure phasing out S2808 and "criminalizing" S2814. *Circ Res* 2012;**110**:1398–1402.
- 42. Pereira L, Cheng H, Lao DH, Na L, van Oort RJ, Brown JH, Wehrens XH, Chen J, Bers DM. Epac2 mediates cardiac β<sub>1</sub>-adrenergic–dependent sarcoplasmic; reticulum Ca<sup>2+</sup> leak and arrhythmia. *Circulation* 2013;**127**:913–922.
- 43. Hidalgo C, Donoso P. Crosstalk between calcium and redox signaling: from molecular mechanisms to health implications. *Antioxid Redox Sign* 2008;**10**:1275–1312.
- 44. Terentyev D, Györke I, Belevych AE, Terentyeva R, Sridhar A, Nishijima Y, de Blanco EC, Khanna S, Sen CK, Cardounel AJ, Carnes CA, Györke S. Redox modification of ryanodine

receptors contributes to sarcoplasmic reticulum Ca<sup>2+</sup> leak in chronic heart failure. *Circ Res* 2008;**103**:1466–1472.

- 45. Bovo E, Lipsius SL, Zima AV. Reactive oxygen species contribute to the development of arrhythmogenic Ca<sup>2</sup> waves during β-adrenergic receptor stimulation in rabbit cardiomyocytes. *J Physiol* 2012;**590**:3291–3304.
- 46. Lipp P, Niggli E. Submicroscopic calcium signals as fundamental events of excitation-contraction coupling in guinea-pig cardiac myocytes. *J Physiol* 1996;**492**:31–38.
- 47. Brochet DXP, Xie W, Yang D, Cheng H, Lederer WJ. Quarky calcium release in the heart. *Circ Res* 2011;**108**:210–218.
- 48. Song T, Hatano N, Kambe T, Miyamoto Y, Ihara H, Yamamoto H, Sugimoto K, Kume K, Yamaguchi F, Tokuda M, Watanabe Y. Nitric oxide-mediated modulation of calcium/calmodulin-dependent protein kinase II. *Biochem J* 2008;**412**:223–231.
- 49. Sarkar D, Vallance P, Amirmansour C, Harding SE. Positive inotropic effects of NO donors in isolated guinea-pig and human cardiomyocytes independent of NO species and cyclic nucleotides. *Cardiovasc Res* 2000;**48**:430–439.
- 50. Joe EK, Schussheim AE, Longrois D, Mäki T, Kelly RA, Smith TW, Balligand JL. Regulation of cardiac myocyte contractile function by inducible nitric oxide synthase (iNOS): mechanisms of contractile depression by nitric oxide. *J Mol Cell Cardiol* 1998:**30**:303–315.
- 51. Ziolo M, Katoh H, Bers D. Positive and negative effects of nitric oxide on Ca<sup>2+</sup> sparks: influence of β-adrenergic stimulation: Nitric oxide-hormones, metabolism, and function. *Am J Physiol Heart Circ Physiol.* 2001;**281**:H2295-H2303.
- 52. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. *Nat Rev Mol Cell Biol* 2005;**6**:150–166.











